Chronic Uveitis: Protecting Your Vision Long Term
Understanding Chronic Uveitis
Uveitis is inflammation of the uvea, the middle layer of the eye. The uvea includes three structures: the iris (the colored part of the eye), the ciliary body (which produces fluid inside the eye), and the choroid (a layer of blood vessels that nourishes the retina). When any of these structures become inflamed, the condition is called uveitis.
When uveitis lasts longer than three months or keeps coming back, it is considered chronic. In one study at a specialized eye center, 56.2% of uveitis patients had chronic disease. This means the condition is not rare. Many people living with uveitis face a long-term challenge rather than a one-time event.
Chronic uveitis is classified by where the inflammation occurs inside the eye. Anterior uveitis affects the front of the eye, including the iris. Intermediate uveitis involves the vitreous gel in the middle of the eye. Posterior uveitis targets the back of the eye, including the choroid and retina. Panuveitis means inflammation is present throughout all layers of the eye.
Each type carries different risks. Posterior uveitis and panuveitis tend to be more serious because inflammation near the retina can directly threaten central vision. The type of uveitis a patient has helps guide the treatment plan.
Repeated episodes of inflammation cause cumulative damage to delicate eye tissues. The harm from chronic uveitis may be greater than the sum of individual flare-ups. Over time, the ongoing inflammation can lead to serious complications. These include macular edema (swelling of the central retina), choroidal neovascularization (abnormal blood vessel growth beneath the retina), cataracts, glaucoma, and even retinal detachment.
These complications can cause lasting loss of visual sharpness. This is why prompt, sustained treatment is so important. The goal is not just to treat each flare-up but to keep inflammation under control continuously.
Who Is Affected and Risk Factors
Uveitis affects a significant number of people in the United States. The adult prevalence of noninfectious uveitis is approximately 121 cases per 100,000 persons (Gritz and Wong, American Journal of Ophthalmology, 2004). More recent data found a cumulative incidence and prevalence of uveitis at 212.5 and 260.8 per 100,000 persons, respectively (American Journal of Ophthalmology, 2025). These numbers highlight that uveitis is more common than many people realize.
Many cases of chronic uveitis are linked to autoimmune or systemic inflammatory diseases. In these conditions, the immune system mistakenly attacks healthy tissue, including the eye. Conditions commonly associated with chronic uveitis include:
- Sarcoidosis
- Ankylosing spondylitis
- Crohn's disease and other forms of inflammatory bowel disease
- Systemic lupus erythematosus
- Rheumatoid arthritis
- Juvenile idiopathic arthritis in children
Certain infections can also cause or trigger chronic uveitis. Infectious causes include herpes simplex virus, varicella-zoster virus (which causes shingles), syphilis, Lyme disease, and toxoplasmosis (a parasitic infection). When infection is the underlying cause, treatment must target both the infection and the inflammation.
Several additional factors can raise the risk of developing chronic uveitis. Smoking cigarettes, cigars, or pipes increases the likelihood of developing the condition. Vitamin D deficiency is also a significant risk factor for noninfectious uveitis. Despite thorough evaluation, the specific cause of chronic uveitis remains unclear in about half of all cases. At least 39% of chronic anterior uveitis cases at specialized centers are classified as idiopathic, meaning no identifiable cause is found (AAO, 2023).
Signs and Symptoms
Chronic uveitis can develop gradually, and symptoms may be mild at first. Common signs include:
- Eye redness that does not go away
- Sensitivity to light, also called photophobia
- Blurred or hazy vision
- Dark floating spots, known as floaters, drifting across your field of view
- Decreased vision in one or both eyes
In some cases, symptoms come on suddenly and worsen quickly. In other cases, they develop slowly over weeks or months. Chronic uveitis may also have periods where symptoms improve, followed by flare-ups where inflammation returns. Some patients have ongoing low-level inflammation without dramatic symptoms. This makes regular monitoring essential.
Certain symptoms require urgent attention. If you experience significant eye pain, a sudden change in vision, a sudden increase in floaters, or flashes of light, see a retina specialist or go to the emergency room immediately. These symptoms could indicate a serious complication such as retinal detachment or a severe inflammatory flare that needs rapid treatment.
Diagnosis and Testing
Diagnosing chronic uveitis begins with a thorough eye examination. A retina specialist will use a slit lamp, a specialized microscope, to look for signs of inflammation in the front and back of the eye. The doctor will check for inflammatory cells floating in the eye's fluid, protein deposits on the inner surface of the cornea, and any structural damage.
Several tests help confirm the diagnosis and determine the cause. Optical coherence tomography, or OCT, produces detailed cross-sectional images of the retina and can detect macular edema. Fluorescein angiography uses a special dye to reveal blood vessel leakage or damage. Blood tests may be ordered to check for autoimmune conditions, infections, or other systemic diseases linked to uveitis.
A newer diagnostic tool, rapid multiplex PCR testing, can identify infectious organisms from a small fluid sample taken from the eye. This test can provide results in less than two hours. It helps guide treatment decisions quickly when infection is suspected.
Finding the cause of chronic uveitis often requires collaboration between a retina specialist and other physicians. These may include a rheumatologist or infectious disease specialist. A detailed medical history, review of symptoms, and targeted testing help narrow down possible causes. Even with extensive testing, the cause remains unknown in a significant number of patients.
Treatment Options
The first line of treatment for chronic uveitis is typically corticosteroid eye drops. These drops reduce inflammation directly inside the eye. Dilating drops are often prescribed at the same time. Dilating drops relax the muscles inside the eye, which reduces pain and helps prevent the iris from sticking to the lens. This complication is called posterior synechiae.
When inflammation is severe or affects the back of the eye, corticosteroid pills such as prednisone may be needed. A typical starting dose for serious cases is 1.0 to 1.5 milligrams per kilogram of body weight per day. However, long-term oral steroid use carries significant side effects. These include weight gain, elevated blood sugar, bone thinning, and increased risk of cataracts and glaucoma. If a patient needs more than 7.5 milligrams per day for longer than three months, a retina specialist will usually consider steroid-sparing alternatives (AAO, 2023).
Steroid-sparing agents help control inflammation while reducing the need for corticosteroids. These medications work by calming the overactive immune response. Common options include methotrexate, mycophenolate, azathioprine, and cyclosporine. The choice of medication depends on the type of uveitis, the underlying cause, and the patient's overall health.
These medications require regular blood tests to monitor for side effects such as changes in liver function or blood cell counts. It may take several weeks before the full benefit is seen.
Adalimumab (Humira) became the first non-corticosteroid therapy approved by the FDA for noninfectious intermediate, posterior, and panuveitis in adults in June 2016. It has since been approved for children aged two years and older with the same types of uveitis. Adalimumab works by blocking a protein called tumor necrosis factor-alpha, or TNF-alpha. This protein plays a key role in the inflammatory process. It is given as a self-administered injection under the skin, typically every two weeks.
For patients with chronic posterior uveitis who need long-term control, sustained-release corticosteroid implants may be an option. The Retisert implant (fluocinolone acetonide) is surgically placed inside the eye and releases a low dose of steroid for approximately 2.5 years. Ozurdex (dexamethasone implant) is another option that is injected into the eye and releases medication over several months. These implants deliver medication directly to the site of inflammation. This can reduce the need for daily eye drops or systemic drugs.
However, implants carry risks including increased eye pressure and cataract formation. Close monitoring by a retina specialist is necessary.
Research is advancing toward new treatment options for chronic uveitis. Baricitinib, a JAK-1,2 inhibitor, is currently in clinical trials for uveitis associated with juvenile idiopathic arthritis. Brepocitinib, a dual TYK2 and JAK-1 inhibitor, is being studied in phase 2 trials. These newer agents represent a growing understanding of the specific immune pathways involved in uveitis. They may offer additional options in the future.
What to Expect
The primary goal of treatment is to eliminate active inflammation, prevent flare-ups, and protect vision. Achieving this takes time. Research shows that remission rates for chronic uveitis are relatively low. Approximately 40% of patients with chronic anterior uveitis achieve remission by five years, with even lower rates for intermediate uveitis and scleritis. This means many patients need ongoing treatment and monitoring for years.
Treatment plans are adjusted over time based on how well inflammation is controlled and how the patient responds. A retina specialist may change medications, adjust doses, or add new therapies as needed.
Regular follow-up appointments are critical for managing chronic uveitis. Even when the eye feels normal, low-level inflammation can persist without obvious symptoms. Routine examinations, OCT scans, and other tests allow a retina specialist to catch early signs of flare-ups or complications before significant damage occurs. The frequency of visits depends on the severity and stability of the condition.
Long-term use of corticosteroids and immunosuppressive medications can cause side effects that need careful management. Patients taking systemic steroids should be monitored for elevated blood sugar, blood pressure changes, and bone density loss. Those on immunosuppressive drugs require regular blood work. Open communication with your retina specialist about any new symptoms or concerns is essential for safe, effective long-term care.
Living with Chronic Uveitis
Living with chronic uveitis means incorporating eye care into your daily routine. Taking prescribed medications on schedule is important, even when symptoms improve. Wearing sunglasses outdoors can help reduce light sensitivity. Keeping a record of symptoms, including when flare-ups occur and what may have triggered them, can help your retina specialist fine-tune your treatment plan.
Because chronic uveitis is often linked to systemic diseases, managing your overall health plays a direct role in eye health. Working with your primary care doctor or rheumatologist to control conditions like inflammatory bowel disease, lupus, or sarcoidosis may reduce the frequency and severity of eye inflammation. If you smoke, quitting can lower your risk of flare-ups. Discussing vitamin D levels with your doctor is also reasonable, given the association between deficiency and noninfectious uveitis.
A chronic eye condition that threatens vision can cause significant stress and anxiety. The uncertainty of flare-ups and the demands of ongoing treatment can be emotionally draining. Support from family, friends, or patient support groups can make a meaningful difference. Speaking with your retina specialist about concerns regarding your condition and its impact on daily life is an important part of your care.
When to See a Retina Specialist
Anyone diagnosed with uveitis that lasts longer than three months or recurs should be evaluated by a retina specialist. A retina specialist, also known as a vitreoretinal surgeon, has advanced training in diagnosing and treating inflammatory conditions affecting the back of the eye. Early involvement of a specialist can help prevent complications that lead to serious vision loss.
Seek immediate medical attention if you experience sudden vision loss, a sudden increase in floaters, flashes of light, or a shadow or curtain spreading across your vision. These symptoms may indicate a retinal detachment or other serious complication that requires emergency care. Do not wait for a scheduled appointment if these symptoms develop.
Questions and Answers
Some patients do achieve long-term remission, but this outcome is not certain for everyone. Research shows that about 40% of chronic anterior uveitis patients reach remission by five years, and rates are lower for other types. Many patients require ongoing treatment or periodic retreatment to keep inflammation under control. A retina specialist will work with you to find the right balance between controlling disease and minimizing medication side effects.
No. While redness and irritation can occur with allergies or minor infections, chronic uveitis involves inflammation inside the eye that can damage structures critical to vision. Surface conditions like allergies affect the conjunctiva, the outer membrane of the eye, and do not typically threaten sight. Chronic uveitis requires specialized diagnosis and treatment that goes well beyond over-the-counter eye drops.
It depends on the type and severity of your condition. Some patients manage well with eye drops and oral medications. Others, particularly those with posterior or panuveitis, may benefit from intravitreal injections (injections of medication directly into the eye) or sustained-release implants. Your retina specialist will recommend the least invasive approach that effectively controls your inflammation.
Yes. Children can develop chronic uveitis, often in association with juvenile idiopathic arthritis. In children, uveitis may cause few symptoms at first. This makes screening eye exams especially important. Adalimumab (Humira) is now FDA-approved for children aged two years and older with noninfectious intermediate, posterior, and panuveitis. It provides an important treatment option for younger patients.
While no specific diet has been proven to treat uveitis, maintaining overall health supports immune function and may reduce the frequency of flare-ups. Quitting smoking is one of the most impactful lifestyle changes, as smoking is a known risk factor for developing uveitis. Ensuring adequate vitamin D intake, through diet or supplements as recommended by your doctor, may also be beneficial. This is supported by the link between vitamin D deficiency and noninfectious uveitis.